AGPAT4-IN-1

Overview

AGPAT4-IN-1 (Compound CL26) is a covalent AGPAT4 inhibitor with an IC 50 of 795 nM. AGPAT4-IN-1 covalently binds to AGPAT4 at Cys 228 and significantly inhibits acyltransferase activity, LPA-to-PA conversion and downstream mTOR/S6K pathways. AGPAT4-IN-1 sensitizes hepatocellular carcinoma (HCC) tumors to Sorafenib ( HY-10201 ) and significantly induces apoptosis with a synergistic response. AGPAT4-IN-1 has antitumor activity and reduces tumorigenicity and stemness in HCC xenograft mouse models.

Application

Products | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Acyltransferase | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > Ribosomal S6 Kinase (RSK) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-175646
• CAS No.: 2411250-59-2
• Molecular Formula: C14H11ClN2O2S
• Molecular Weight: 306.77
• Purity: 99.04%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (16.30 mM); Clear solution
• Availability: In-stock

Source

Original product source